- Wednesday, June 15, 2022
- IPC GENERAL
- COVID-19, IPC Partners, Research
PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases. Below is a summary of the data collected or view the full report on the PsoProtect website.
Average age: 48 years
Phenotype of psoriasis: 1,605 plaque psoriasis, 47 pustular psoriasis
Average BMI: 27.7 kg/m2
Average number of days of symptoms from COVID-19: 10 days
Cases reported by country of assessment (≥20 cases):

Severity of psoriasis at time of onset of COVID-19 (PGA):

Hospitalization required due to COVID-19:

In addition to demographics, PsoProtect collects the following types of de-identified data:
- Psoriasis disease characteristics, comorbidities and systemic treatment for psoriasis at onset of COVID-19
- COVID-19 characteristics and disease course
- COVID-19 outcome
We encourage clinicians to continue reporting cases of COVID-19 (suspected or confirmed) in psoriasis via the simple online PsoProtect case report form.
*Data are preliminary and include a limited number of cases and should not be used to inform clinical decision making